DE60208701D1 - Verwendung von cetrorelix zur behandlung vom jakob-creutzfeldt-syndrom - Google Patents
Verwendung von cetrorelix zur behandlung vom jakob-creutzfeldt-syndromInfo
- Publication number
- DE60208701D1 DE60208701D1 DE60208701T DE60208701T DE60208701D1 DE 60208701 D1 DE60208701 D1 DE 60208701D1 DE 60208701 T DE60208701 T DE 60208701T DE 60208701 T DE60208701 T DE 60208701T DE 60208701 D1 DE60208701 D1 DE 60208701D1
- Authority
- DE
- Germany
- Prior art keywords
- cetrorelix
- creutzfeldt
- jakob
- syndrome
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Virology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE60208701T DE60208701T2 (de) | 2001-07-31 | 2002-07-30 | Verwendung von cetrorelix zur behandlung vom jakob-creutzfeldt-syndrom |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10137174A DE10137174A1 (de) | 2001-07-31 | 2001-07-31 | Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität |
DE10137174 | 2001-07-31 | ||
DE60208701T DE60208701T2 (de) | 2001-07-31 | 2002-07-30 | Verwendung von cetrorelix zur behandlung vom jakob-creutzfeldt-syndrom |
PCT/EP2002/008459 WO2003011314A2 (en) | 2001-07-31 | 2002-07-30 | Use of lhrh-antagonists for the improvement of t-cell mediated immunity |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60208701D1 true DE60208701D1 (de) | 2006-04-06 |
DE60208701T2 DE60208701T2 (de) | 2006-08-10 |
Family
ID=7693650
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE10137174A Withdrawn DE10137174A1 (de) | 2001-07-31 | 2001-07-31 | Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität |
DE60208701T Expired - Fee Related DE60208701T2 (de) | 2001-07-31 | 2002-07-30 | Verwendung von cetrorelix zur behandlung vom jakob-creutzfeldt-syndrom |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE10137174A Withdrawn DE10137174A1 (de) | 2001-07-31 | 2001-07-31 | Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP1414481B1 (de) |
JP (1) | JP2005500348A (de) |
KR (1) | KR20040028957A (de) |
CN (1) | CN1525865A (de) |
AR (1) | AR034954A1 (de) |
AT (1) | ATE315400T1 (de) |
BR (1) | BR0211498A (de) |
CA (1) | CA2452524A1 (de) |
DE (2) | DE10137174A1 (de) |
HR (1) | HRP20040186B1 (de) |
HU (1) | HUP0401634A2 (de) |
IL (1) | IL159285A0 (de) |
MX (1) | MXPA04000870A (de) |
NO (1) | NO20040350L (de) |
NZ (1) | NZ531263A (de) |
PL (1) | PL364492A1 (de) |
RU (1) | RU2004106545A (de) |
WO (1) | WO2003011314A2 (de) |
ZA (1) | ZA200309889B (de) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL147138A0 (en) * | 2001-12-17 | 2002-08-14 | Yeda Res & Dev | Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation |
EP1891964A1 (de) * | 2006-08-08 | 2008-02-27 | AEterna Zentaris GmbH | Anwendung von Anfangsdosen von LHRH-Analogen und Erhaltungsdosen von LHRH-Antagonisten zur Behandlung von hormonabhängigen Krebsarten und entsprechende Kits |
RU2010113977A (ru) * | 2007-09-11 | 2011-10-20 | Мондобайотек Лабораториз Аг (Li) | Применение антагониста рецептора фибриногена и/или пептид фолликулярного гонадолиберина в качестве терапевтического средства при лечении инфекции streptococcus pneumoniae |
WO2009043455A2 (en) * | 2007-09-11 | 2009-04-09 | Mondobiotech Laboratories Ag | Therapeutic uses of angiogenin 108-122 and gluten exorphin a5 |
EP2095818A1 (de) * | 2008-02-29 | 2009-09-02 | AEterna Zentaris GmbH | Verwendung von LHRH-Antagonisten in nicht-kastrierenden Dosen |
CA2750582A1 (en) * | 2009-01-22 | 2010-07-29 | Maatschap Interne Geneeskunde Rijnstate | Method for the prophylaxis or treatment of flushing |
CA2958939A1 (en) | 2014-08-26 | 2016-03-03 | Betanien Hospital | Methods, agents and compositions for treatment of inflammatory conditions |
CN107007814B (zh) * | 2016-11-04 | 2020-03-17 | 中国科学院昆明动物研究所 | 西曲瑞克在制备治疗艾滋病的药物中的应用 |
CN108066763A (zh) * | 2017-12-21 | 2018-05-25 | 陈敏 | Pcsk9抑制剂在制备治疗t细胞介导的炎症免疫性疾病药中的应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04504760A (ja) * | 1989-09-25 | 1992-08-20 | アメリカ合衆国 | 炎症性反応の検出およびストレスに対する応答の予測をするための評価方法 |
DE4320201A1 (de) * | 1993-06-18 | 1995-01-12 | Asta Medica Ag | Verwendung von Cetrorelix und weiteren Nona- und Dekapeptiden zur Herstellung eines Arzneimittels zur Bekämpfung von Aids und zur Wachstumsstimulation |
DE4342091A1 (de) * | 1993-12-09 | 1995-06-14 | Asta Medica Ag | Erzeugnisse zur Anwendung von initial hohen Dosen von Cetrorelix und Herstellung einer Kombinationspackung zur Verwendung bei Therapie von Krankheiten |
CN1137722C (zh) * | 1994-07-22 | 2004-02-11 | 汉普顿路医学院 | 为长期治疗方案确立基础(tonic)卵巢雌激素分泌 |
CA2173727A1 (en) * | 1994-08-10 | 1996-02-22 | Sandor Lovas | Novel gnrh analogues with antitumour effects and pharmaceutical compositions thereof |
WO1996022786A1 (en) * | 1995-01-23 | 1996-08-01 | Takeda Chemical Industries, Ltd. | Sustained-release preparation and use |
US5780435A (en) * | 1995-12-15 | 1998-07-14 | Praecis Pharmaceuticals Incorporated | Methods for treating prostate cancer with LHRH-R antagonists |
US6054432A (en) * | 1996-09-12 | 2000-04-25 | Asta Medica Aktiengesellschaft | Means for treating prostate hypertrophy and prostate cancer |
CA2309855A1 (en) * | 1997-11-24 | 1999-06-03 | Katherine D. Gordon | Testosterone inhibitors and use for the protection of neurons |
US20020071829A1 (en) * | 1999-04-15 | 2002-06-13 | Richard Boyd | Normalization of defective T cell responsiveness through manipulation of thymic regeneration |
US20020119128A1 (en) * | 2000-04-17 | 2002-08-29 | Richard Boyd | Graft acceptance through manipulation of thymic regeneration |
WO2001078780A1 (fr) * | 2000-04-13 | 2001-10-25 | Takeda Chemical Industries, Ltd. | Agents preventifs/remedes pour la maladie d'alzheimer |
EP1392348B1 (de) * | 2001-04-30 | 2008-07-09 | AEterna Zentaris GmbH | Niedrigdosierte lhrh antagonisten zur behandlung von neurodegenerativen krankheiten, insbesondere alzheimer krankheit |
US20030144203A1 (en) * | 2001-12-19 | 2003-07-31 | Voyager Pharmaceutical Corporation | Methods for slowing senescence and treating and preventing diseases associated with senescence |
-
2001
- 2001-07-31 DE DE10137174A patent/DE10137174A1/de not_active Withdrawn
-
2002
- 2002-07-30 KR KR10-2004-7001327A patent/KR20040028957A/ko not_active Application Discontinuation
- 2002-07-30 CN CNA028136993A patent/CN1525865A/zh active Pending
- 2002-07-30 RU RU2004106545/15A patent/RU2004106545A/ru not_active Application Discontinuation
- 2002-07-30 EP EP02767276A patent/EP1414481B1/de not_active Expired - Lifetime
- 2002-07-30 PL PL02364492A patent/PL364492A1/xx unknown
- 2002-07-30 MX MXPA04000870A patent/MXPA04000870A/es unknown
- 2002-07-30 BR BR0211498-4A patent/BR0211498A/pt not_active IP Right Cessation
- 2002-07-30 WO PCT/EP2002/008459 patent/WO2003011314A2/en active IP Right Grant
- 2002-07-30 HU HU0401634A patent/HUP0401634A2/hu unknown
- 2002-07-30 JP JP2003516544A patent/JP2005500348A/ja not_active Withdrawn
- 2002-07-30 NZ NZ531263A patent/NZ531263A/en unknown
- 2002-07-30 DE DE60208701T patent/DE60208701T2/de not_active Expired - Fee Related
- 2002-07-30 IL IL15928502A patent/IL159285A0/xx unknown
- 2002-07-30 AT AT02767276T patent/ATE315400T1/de not_active IP Right Cessation
- 2002-07-30 CA CA002452524A patent/CA2452524A1/en not_active Abandoned
- 2002-07-31 AR ARP020102902A patent/AR034954A1/es unknown
-
2003
- 2003-12-22 ZA ZA200309889A patent/ZA200309889B/en unknown
-
2004
- 2004-01-26 NO NO20040350A patent/NO20040350L/no not_active Application Discontinuation
- 2004-02-25 HR HR20040186A patent/HRP20040186B1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ZA200309889B (en) | 2004-02-19 |
ATE315400T1 (de) | 2006-02-15 |
WO2003011314A2 (en) | 2003-02-13 |
DE10137174A1 (de) | 2003-02-13 |
WO2003011314A3 (en) | 2003-10-16 |
RU2004106545A (ru) | 2005-04-10 |
NZ531263A (en) | 2005-05-27 |
JP2005500348A (ja) | 2005-01-06 |
AR034954A1 (es) | 2004-03-24 |
CA2452524A1 (en) | 2003-02-13 |
DE60208701T2 (de) | 2006-08-10 |
HRP20040186A2 (en) | 2004-08-31 |
IL159285A0 (en) | 2004-06-01 |
NO20040350L (no) | 2004-01-26 |
EP1414481A2 (de) | 2004-05-06 |
KR20040028957A (ko) | 2004-04-03 |
CN1525865A (zh) | 2004-09-01 |
PL364492A1 (en) | 2004-12-13 |
HUP0401634A2 (hu) | 2004-12-28 |
BR0211498A (pt) | 2004-08-17 |
MXPA04000870A (es) | 2004-06-03 |
HRP20040186B1 (en) | 2007-05-31 |
EP1414481B1 (de) | 2006-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE512163T1 (de) | Verabreichung von mitteln zur behandlung von entzündungen | |
DE60230425D1 (de) | Phenethanolamin-derivate zur behandlung von erkrankungen der atemwege | |
DE60124302D1 (de) | Thiazolderivate zur behandlung von ppar-lierte krankheiten | |
DE60218493D1 (de) | Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten | |
IS7099A (is) | Efnasambönd til að meðhöndla bólgutruflanir | |
DE69910368D1 (de) | Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen | |
DE60335560D1 (de) | Zusammensetzungen enthaltend zitronensäure zur behandlung von nagelpilzerkrankungen | |
DE60235083D1 (de) | Substituierte tetracyclin-verbindungen zur behandlung von malaria | |
DE60113496D1 (de) | Verwendung von Glycyrrhizin zur Behandlung von Mastitis. | |
DE60123238D1 (de) | Zusammensetzungen zur behandlung von autoimmunkrankheiten | |
DE50214540D1 (de) | Stanz bei der behandlung von wunden | |
DE60234760D1 (de) | Phenylindole zur behandlung von hiv | |
DE60136477D1 (de) | Retinoide zur behandlung von emphysem | |
DE60204466D1 (de) | Integrinhemmer zur behandlung von augenkrankheiten | |
ATE369130T1 (de) | Carbamatverbindungen zur vorbeugung und behandlung von bewegungsstörungen | |
DE60239220D1 (de) | ClC-2-KANALÖFFNER ZUR BEHANDLUNG VON MAGEN- ODER DARM-ULCUS | |
DE60236743D1 (de) | Zur behandlung androgenabhängiger krankheiten | |
DE50013843D1 (de) | Arzneimittel zur behandlung von darmerkrankungen | |
DE60328494D1 (de) | Verbessertes system zur behandlung der stressbedingten harninkontinenz | |
DE60208701D1 (de) | Verwendung von cetrorelix zur behandlung vom jakob-creutzfeldt-syndrom | |
DE60238765D1 (de) | Carbamatverbindungen zur behandlung von schmerz | |
ATE337787T1 (de) | Exemestan zur behandlung von hormonabhängigen störungen | |
DE60206289D1 (de) | Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne | |
DE50205466D1 (de) | Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen | |
ATE273276T1 (de) | Cyclobutendion-derivate zur behandlung von artherosclerose |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: AETERNA ZENTARIS GMBH, 60314 FRANKFURT, DE |
|
8339 | Ceased/non-payment of the annual fee |